

- **Full Name:** Dae Ho Lee
- **Current Position & Affiliation:** Professor, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center
- Country:** Republic of Korea
-

• **Educational Background:**

- 1987.3. ~ 1994.2 MD, College of Medicine, Seoul National University, Seoul, Republic of Korea
- 1999.3. ~ 2001.2. MS, Postgraduate School, Seoul National University, Seoul, Republic of Korea
- 2002. 9. ~ 2007.2. PhD, Postgraduate School, Seoul National University, Seoul, Republic of Korea

• **Professional Experience:**

- 2002. 4 ~ 2006. 2. Medical Oncologist, Center for Specific Organs Cancer and Center for Lung Cancer, National Cancer Center Hospital, Goyang, Gyeonggi-do, Republic of Korea
- 2006. 3 – 2006. 8 Instructor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 2006. 9. ~ 2011. 9. Assistant Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 2011. 10 – 2017. 9. Associate Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 2017.10 ~ present Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

• **Professional Organizations:**

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Cancer Association
- Member, Korean Society of Medical Oncology
- Member, Korean Cancer Study Group
- Member, Korean Association for Lung Cancer
- Member, Korean Association of Institutional Review Board
- Member, International Association for the Study of Lung Cancer
- Member, American Society of Clinical Oncology
- Member, American Association for Cancer Research
- Member, European Society for Medical Oncology

• Main Scientific Publications:

1. Lee DH. Treating Oligometastases, Prelude or Just Hassles of Systemic Treatment. *Cancer Res Treat.* 2022;54(4):951-952,
2. Yoon S, Yang H, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Jung KH, Park SR, Choi EK, Kim SW, Park KS, Lee DH. Integrin $\alpha\beta3$ Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer. *Cancer Res Treat.* 2022;54(3):767-781.
3. Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hirt S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. *Lancet Oncol.* 2022;23(6):781-792
4. Lee J, Tan AC, Zhou S, Yoon S, Liu S, Masuda K, Hayashi H, Batra U, Kim DW, Goto Y, Tan SH, Wu YL, Lee DH, Tan DSW, Ahn MJ. Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). *JTO Clin Res Rep.* 2021;3(1):100261.
5. Lee DH. The Law Changes Behaviors: Is It Just Enough? *Cancer Res Treat.* 2021;53(4):895-896.
6. Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. *JAMA Oncol.* 2021;7(11):1617-1625.
7. Cho BC, Yoh K, Perets R, Nagrial A, Spigel DR, Gutierrez M, Kim DW, Kotasek D, Rasco D, Niu J, Satouchi M, Ahn MJ, Lee DH, Maurice-Dror C, Siddiqi S, Ren Y, Altura RA, Bar J. Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. *Lung Cancer.* 2021;159:162-170.
8. Dziadziuszko R, Mok T, Peters S, Han JY, Alatorre-Alexander J, Leighl N, Sriuranpong V, Pérol M, de Castro Junior G, Nadal E, de Marinis F, Frontera OA, Tan DSW, Lee DH, Kim HR, Yan M, Riehl T, Schleifman E, Paul SM, Mocchi S, Patel R, Assaf ZJ, Shames DS, Mathisen MS, Gadgeel SM Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. *J Thorac Oncol.* 202;16(12):2040-2050.
9. Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol.* 2021;22(7):959-969.

10. Lee K, Kim D, Yoon S, Lee DH, Kim SW Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer. *Eur J Cancer*. 2021;148:202-210.
11. Boyer M, Şendur MAN, Rodríguez-Abreu D, Park K, Lee DH, Çiçin I, Yumuk PF, Orlandi FJ, Leal TA, Molinier O, Soparattanapaisarn N, Langleben A, Califano R, Medgyasszay B, Hsia TC, Otterson GA, Xu L, Piperdi B, Samkari A, Reck M. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non- small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study ; KEYNOTE-598 Investigators. *J Clin Oncol*. 2021;39(21):2327-2338.
12. Park K, Jänne PA, Kim DW, Han JY, Wu MF, Lee JS, Kang JH, Lee DH, Cho BC, Yu CJ, Pang YK, Felip E, Kim H, Baek E, Noh YS . Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. *Cancer*. 2021;127(9):1407-1416
13. Lee DH. Update of early phase clinical trials in cancer immunotherapy. *BMB Rep*. 2021;54(1):70-88.
14. Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. *Clin Cancer Res*. 2021;27(4):992-1002.